Alexandra Thomas
Overview
Explore the profile of Alexandra Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnone A, Tsai Y, Cline J, Wilson A, Westwood B, Seger M, et al.
Cell Rep Med
. 2025 Jan;
6(1):101880.
PMID: 39742868
Studies indicate that breast tissue has a distinct modifiable microbiome population. We demonstrate that endocrine-targeting therapies, such as tamoxifen, reshape the non-cancerous breast microbiome to influence tissue metabolism and reduce...
2.
Sharma S, Wu S, Jimenez H, Xing F, Zhu D, Liu Y, et al.
EBioMedicine
. 2024 Dec;
111():105541.
PMID: 39731855
No abstract available.
3.
Danhauer S, Tooze J, Abubaker T, Graves K, Kerr N, Howard D, et al.
J Psychosoc Oncol
. 2024 Dec;
1-16.
PMID: 39731277
Purpose/objectives: Hispanic and Latino (hereafter 'H/L') cancer survivors report higher rates of anxiety/depression and are less likely to receive psychosocial services than other survivors. We field-tested a culturally and linguistically...
4.
OReilly S, Lynch E, Hwang E, Brown M, ODonovan T, Hennessy M, et al.
Clin Breast Cancer
. 2024 Dec;
PMID: 39668009
Climate change is the greatest threat to human existence. Currently it impacts breast cancer care by disrupting treatment, by food poverty and economic hardship and through fossil fuel pollution which...
5.
Regua A, Aguayo N, Jalboush S, Doheny D, Manore S, Zhu D, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410053
In the original publication [...].
6.
Thomas A, Mayer E, DeMichele A, Harbeck N, Curigliano G, Ignatiadis M, et al.
J Clin Oncol
. 2024 Oct;
43(5):487-491.
PMID: 39383501
Harmonized global collaborations are crucial to improving outcomes in hormone sensitive operable breast cancer.
7.
Shatsky R, Trivedi M, Yau C, Nanda R, Rugo H, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3737-3747.
PMID: 39277672
Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan...
8.
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3728-3736.
PMID: 39277671
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer...
9.
Thomas A, Broderick A, Anders C
JCO Oncol Pract
. 2024 Jun;
20(8):1003-1005.
PMID: 38917387
No abstract available.
10.
Daly A, Newman L, Thomas A, Munro A, Spence C, Long J, et al.
Front Nutr
. 2024 May;
11:1366768.
PMID: 38716071
Introduction: Specific body composition markers derived from L3 axial computed tomography (CT) images predict clinical cancer outcomes, including chemotherapy toxicity and survival. However, this method is only applicable to those...